PatientsVille.com Logo

DIARRHOEA and Pradaxa

PatientsVille

DIARRHOEA Symptoms and Causes

What is diarrhea?

Diarrhea is loose, watery stools (bowel movements). You have diarrhea if you have loose stools three or more times in one day. Acute diarrhea is diarrhea that lasts a short time. It is a common problem. It usually lasts about one or two days, but it may last longer. Then it goes away on its own.

Diarrhea lasting more than a few days may be a sign of a more serious problem. Chronic diarrhea -- diarrhea that lasts at least four weeks -- can be a symptom of a chronic disease. Chronic diarrhea symptoms may be continual, or they may come and go.

What causes diarrhea?

The most common causes of diarrhea include

  • Bacteria from contaminated food or water
  • Viruses such as the flu, norovirus, or rotavirus . Rotavirus is the most common cause of acute diarrhea in children.
  • Parasites, which are tiny organisms found in contaminated food or water
  • Medicines such as antibiotics, cancer drugs, and antacids that contain magnesium
  • Food intolerances and sensitivities, which are problems digesting certain ingredients or foods. An example is lactose intolerance.
  • Diseases that affect the stomach, small intestine, or colon, such as Crohn's disease
  • Problems with how the colon functions, such as irritable bowel syndrome

Some people also get diarrhea after stomach surgery, because sometimes the surgeries can cause food to move through your digestive system more quickly.

Sometimes no cause can be found. If your diarrhea goes away within a few days, finding the cause is usually not necessary.

Who is at risk for diarrhea?

People of all ages can get diarrhea. On average, adults In the United States have acute diarrhea once a year. Young children have it an average of twice a year.

People who visit developing countries are at risk for traveler's diarrhea. It is caused by consuming contaminated food or water.

What other symptoms might I have with diarrhea?

Other possible symptoms of diarrhea include

  • Cramps or pain in the abdomen
  • An urgent need to use the bathroom
  • Loss of bowel control

If a virus or bacteria is the cause of your diarrhea, you may also have a fever, chills, and bloody stools.

Diarrhea can cause dehydration, which means that your body does not have enough fluid to work properly. Dehydration can be serious, especially for children, older adults, and people with weakened immune systems.

When should I see a doctor for diarrhea?

Although it is usually not harmful, diarrhea can become dangerous or signal a more serious problem. Contact your health care provider if you have

  • Signs of dehydration
  • Diarrhea for more than 2 days, if you are an adult. For children, contact the provider if it lasts more than 24 hours.
  • Severe pain in your abdomen or rectum (for adults)
  • A fever of 102 degrees or higher
  • Stools containing blood or pus
  • Stools that are black and tarry

If children have diarrhea, parents or caregivers should not hesitate to call a health care provider. Diarrhea can be especially dangerous in newborns and infants.

How is the cause of diarrhea diagnosed?

To find the cause of diarrhea, your health care provider may

  • Do a physical exam
  • Ask about any medicines you are taking
  • Test your stool or blood to look for bacteria, parasites, or other signs of disease or infection
  • Ask you to stop eating certain foods to see whether your diarrhea goes away

If you have chronic diarrhea, your health care provider may perform other tests to look for signs of disease.

What are the treatments for diarrhea?

Diarrhea is treated by replacing lost fluids and electrolytes to prevent dehydration. Depending on the cause of the problem, you may need medicines to stop the diarrhea or treat an infection.

Adults with diarrhea should drink water, fruit juices, sports drinks, sodas without caffeine, and salty broths. As your symptoms improve, you can eat soft, bland food.

Children with diarrhea should be given oral rehydration solutions to replace lost fluids and electrolytes.

Can diarrhea be prevented?

Two types of diarrhea can be prevented - rotavirus diarrhea and traveler's diarrhea. There are vaccines for rotavirus. They are given to babies in two or three doses.

You can help prevent traveler's diarrhea by being careful about what you eat and drink when you are in developing countries:

  • Use only bottled or purified water for drinking, making ice cubes, and brushing your teeth
  • If you do use tap water, boil it or use iodine tablets
  • Make sure that the cooked food you eat is fully cooked and served hot
  • Avoid unwashed or unpeeled raw fruits and vegetables

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for DIARRHOEA

DIARRHOEA treatment research studies

Pradaxa clinical trials, surveys and public health registries


Find Drug Side Effect reports



Pradaxa Side Effects

Gastrointestinal Haemorrhage (2049)
Anaemia (785)
Cerebrovascular Accident (760)
Haemorrhage (724)
Fall (618)
Rectal Haemorrhage (581)
Renal Failure Acute (471)
Dizziness (465)
Dyspepsia (439)
Haemorrhagic Anaemia (428)
Coagulopathy (420)
Dyspnoea (414)
Ischaemic Stroke (406)
Contusion (388)
Epistaxis (381)
Nausea (379)
Melaena (366)
Haemoglobin Decreased (363)
Asthenia (351)
Death (342)
Cerebral Haemorrhage (303)
Lower Gastrointestinal Haemorrhage (292)
Diarrhoea (283)
Haematuria (281)
Atrial Fibrillation (279)
Upper Gastrointestinal Haemorrhage (267)
Headache (267)
Pulmonary Embolism (264)
Haematochezia (264)
Deep Vein Thrombosis (258)
Myocardial Infarction (252)
Fatigue (246)
International Normalised Ratio Increased (241)
Haemorrhage Intracranial (239)
Renal Failure (235)
Arthralgia (230)
Transient Ischaemic Attack (218)
Abdominal Pain Upper (213)
Cerebral Infarction (207)
Chest Pain (207)
Abdominal Discomfort (198)
Pneumonia (192)
Vomiting (190)
Haematoma (181)
Abdominal Pain (178)
Subdural Haematoma (170)
Pain In Extremity (164)
Oedema Peripheral (164)
Renal Impairment (160)
Haemoptysis (156)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I'm over 80, very active working 6 days a week, walking briskly about 6 x 10 minutes daily, with Verapamil and 100 mg aspirin (also diabetic and asthmatic - completely under control). Had a biological aortic valve replacement, very s

While taking Pradaxa I had severe knife feeling pain in left eye. I have been off 2 days and it is better. I will check with eye docotr this week and see if it is eye or meds.

I have been Pradaxa for almost a month had severe outbreak of hives on my feet and my legs up to my knees. I also having swelling of legs and feet along with fatigue in joints and body limbs. Doctor changed my Med. but the side effects is still o

3 MONTHS TAKING PRADAXA WITH NO SIDE EFFECTS

Since taking Prodaxa I am experiencing shortness of breath...

I been taking pradaxa for 14 days and have a severe rash, doctor to start warfarin again.

my husband has been on pradaxa for a month he cannot eat has lost 26 lbs gets chills and then feels hot, vomiting.

Want to know if it could cause my extreme tiredness.

<b>Describe Your Pradaxa Experience Here:</b>tired and fluid retention

<b>Describe Your Pradaxa Experience Here:</b>itching that last five minutes and goes away i have swelled knee pain also arthritis

Abdominal pain, diarrhoea, headache, joint swelling (psoriasis flare), sore eyes, increase in hot flushes.

After being diagnosed with dermographism, I was prescibed the above drugs, to be taken together. I assume that Zantac offers some protection for the stomach. Unfortunately, I experienced nausea, vomiting, stomach cramps and diarrhoea whithin an hour

An addition to Frances Wedderburn's side effects from Januvia, some of my Liver Enzymes became elevated. They decreased when checked 10 days after stopping Januvia. Diarrhoea continues

Bitter-sour taste in the morning and bedtime. Bloated feeling plus diarrhoea. Extremely lethargic all day. Unnatural deep night sleep.

Can diabex cause chronic diarrhoea ? I have been using diabex for 11 years

Day 2..felt nauseus, headache, couldnt sleep, day 3..vomited, diarrhoea, sweating abdominal cramps and pain, Im off them!! I feel like Im going to die I feel so sick DON'T TAKE CHAMPIX!

Diabex has caused diarrhoea and agonizing pelvic/bowel pains.

Extreme pain in left side, diarrhoea for several weeks, one collapse

Having taken only my firstterbinafine tabletyesterday I was o.k but had diarrhoea today. I took a second tablet on day 2, and felt sick and giddy with slightly blurred visionan hour later.&a

Hi, i sufer from gastric ulcer and im treated with colofac and pantoprazole and after abaute 3days of using these drugs i experienced the diarrhoea and i had it for 2 weeks. so i left using colofac and every thing was going good for 2days, but after

DIARRHOEA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Management of Myocardial Injury After Noncardiac Surgery Trial
Condition: Myocardial Injury After Noncardiac Surgery (MINS)
Interventions: Drug: Dabigatran;   Drug: Placebo (for Dabigatran);   Drug: Omeprazole;   Drug: Placebo (for Omeprazole)
Outcome Measures: Major vascular complication (for Dabigatran);   Major upper gastrointestinal complication (for Omeprazole);   Individual secondary outcomes for Dabigatran;   Upper gastrointestinal complication for Omeprazole;   Major vascular complication for Omeprazole;   Individual secondary outcomes for Omeprazole;   Safety outcomes for Dabigatran;   Safety outcomes for Omeprazole
2 Recruiting Strategy of Continued Versus Interrupted Dabigatran at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Condition: Hematoma
Intervention: Drug: Dabigatran
Outcome Measures: Clinically significant hematoma;   Composite of major peri-operative bleeding events and thrombo-embolic events
3 Recruiting Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
Condition: Primary Disease
Interventions: Drug: Dabigatran;   Drug: Warfarin
Outcome Measures: Embolic Events;   Bleeding
4 Recruiting SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
Condition: Atrial Fibrillation
Intervention: Drug: Pradaxa (Dabigatran etexilate mesilate)
Outcome Measures: Occurrence of adverse events;   Incidence rate of stroke;   Incidence rate of systemic embolism
5 Recruiting Drug Interaction Study Between Bosutinib And Dabigatran
Condition: Healthy
Interventions: Drug: Dabigatran;   Drug: Bosutinib
Outcome Measures: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Maximum Observed Plasma Concentration (Cmax);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2);   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F)
6 Recruiting Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Drug: Dabigatran etexilate (Pradaxa)
Outcome Measure: Percentage of fibrosis
7 Recruiting Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke
Conditions: Transient Ischemic Attack;   Minor Ischemic Stroke
Intervention: Drug: Dabigatran 110/150 mg BID
Outcome Measure: Symptomatic Hemorrhagic Transformation
8 Recruiting Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Conditions: Atrial Fibrillation;   Atrial Flutter
Intervention: Drug: dabigatran etexilate mesylate
Outcome Measures: Frequency of major bleeding complications and thrombo-embolic events in patients administered dabigatran following RF ablation.;   Dabigatran serum drug levels in patients experiencing a major bleeding or thrombo-embolic event.;   Frequency of minor bleeding events
9 Recruiting Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
Condition: Atrial Fibrillation
Intervention: Drug: Pradaxa, dabigatran etexilate
Outcome Measures: Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose;   Concentration of analyte in plasma at steady state at 2 hours after administration of the last dose
10 Recruiting Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
Condition: Venous Thromboembolism
Interventions: Drug: dabigatran etexilate;   Drug: standard of care
Outcome Measures: First component of the co-primary endpoint: A combined efficacy endpoint of complete thrombus resolution plus freedom from recurrent VTE plus freedom from mortality related to VTE;   Second component of the co-primary endpoint: Freedom from major bleeding events (a safety endpoint);   Pharmacokinetic assessments (plasma concentrations of total dabigatran) 3 days after start of treatment (after at least six consecutive dabigatran doses) and after 3 days following any dabigatran dose adjustment;   Frequency of dose adjustments;   Frequency of switch of type of anti-coagulation therapy (including dabigatran to SOC) and a switch from an intended standard of care treatment to another;   Freedom from thrombus progression at baseline and at days 21 and 84 after randomisation;   Assessment of the acceptability of an age-appropriate formulation at end of therapy;   Freedom from recurrence of VTE at 6, 9 and 12 months;   Freedom from occurrence of post-thrombotic syndrome at 6, 9 and 12 months;   All bleeding events;   All-cause mortality;   All components of the primary efficacy endpoints;   Pharmacodynamic assessments (aPTT, ecarin clotting time (ECT) and dTT) 3 days after start of treatment (after at least six consecutive dabigatran doses) and after 3 days following any dabigatran dose adjustment;   Frequency of temporary discontinuation from therapy;   Frequency of permanent discontinuation from therapy;   Number of laboratory monitoring requirements for dose adjustment during the treatment phase
11 Recruiting Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Condition: Venous Thromboembolism
Intervention: Drug: dabigatran etexilate
Outcome Measures: Plasma concentrations of total dabigatran;   Plasma concentrations of free dabigatran;   Plasma concentrations of BIBR 1048 BS (Base);   Plasma concentrations of BIBR 951 BS;   Plasma concentrations of BIBR 1087 SE (Acid);   Activated prothrombin time (aPTT);   Ecarin clotting time (ECT);   Factor IIa inhibition;   Incidence of all bleeding events;   Incidence of all adverse events;   Global assessment of tolerability will be summarized across all patients in the treated set;   Patient assessment of taste will be summarized across all patients in the treated set;   Changes in laboratory and clinical parameters
12 Recruiting Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
Conditions: Coronary Heart Disease;   Atrial Fibrillation;   Acute Coronary Syndrome;   Atherosclerosis
Interventions: Drug: Dabigatran;   Drug: Phenprocoumon
Outcome Measures: ADP induced platelet aggregation;   Platelet function tests;   Coagulation parameters
13 Not yet recruiting Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
Condition: Venous Thrombembolic Events.
Intervention: Drug: Dabigatran.
Outcome Measure: Validation of a novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
14 Not yet recruiting Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
Conditions: Atrial Fibrillation;   Hemorrhage
Interventions: Drug: Dabigatran 75 mg;   Drug: Dabigatran 150 mg
Outcome Measures: Number of patients with index event safety outcomes (ongoing/resolved/deceased);   Number of patients receiving different types of interventions to stop the index events;   Frequencies of bleeding types and anatomic locations of the index event
15 Recruiting Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
Condition: Venous Thromboembolism
Intervention: Drug: dabigatran etexilate
Outcome Measures: Ecarin clotting time (ECT);   Factor IIa inhibition;   Incidence of all bleeding events;   Incidence of all adverse events;   Plasma concentrations of total dabigatran;   Plasma concentrations of free dabigatran;   Plasma concentrations of BIBR 1048 BS (Base);   Plasma concentrations of BIBR 951 BS;   Plasma concentrations of BIBR 1087 SE (Acid);   Activated prothrombin time (aPTT);   Global assessment of tolerability will be summarized across all patients in the treated set;   Patient assessment of taste will be summarized across all patients in the treated set;   Changes in laboratory and clinical parameters
16 Recruiting Safety Study of Dabigatran in CADASIL
Condition: CADASIL
Interventions: Drug: Dabigatran;   Drug: Antiplatelets
Outcome Measures: Number of microbleeds on MRI;   Major bleeding
17 Not yet recruiting Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
Condition: Atrial Fibrillation
Interventions: Drug: Warfarin;   Drug: Dabigatran
Outcome Measures: Cognitive impairment;   Number of Participants with less important alteration in coagulation test as a Measure of Safety
18 Recruiting Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Condition: Hemorrhage
Intervention: Drug: idarucizumab
Outcome Measures: Reversal of anticoagulant effect of dabigatran;   Reversal of Activated Partial Thromboplastin Time (aPTT);   Reversal of Thrombin Time (TT);   Duration of reversal;   Occurrence of major bleeding post-surgery (for Group B only);   Time to cessation of bleeding (for Group A only);   Minimum unbound sum (free) dabigatran;   Reversal of diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) after the first infusion and before the start of the second
19 Recruiting Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
Condition: Healthy Volunteers
Interventions: Drug: D->R->C+R;   Drug: D->R->C+D;   Drug: R->D->C+D;   Drug: R->D->C+R
Outcome Measures: AUC of plasma concentrations of the drugs;   PKD of the drugs
20 Recruiting Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
Conditions: Arthroplasty, Replacement;   Thromboembolism
Intervention:
Outcome Measures: Safety: Major bleeding events. Efficacy: composite of all death and documented symptomatic VTE (i.e documented symptomatic DVT and documented symptomatic nonfatal pulmonary embolism).;   Major extra surgical site bleedings,volume of wound drainage, documented symptomatic proximal DVT, documented symptomatic distal DVT, documented symptomatic nonfatal pulmonary embolism and all-cause mortality